The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)

Health and Quality of Life Outcomes

Volumn 10, Issue , 2012, Pages

  Cima, Katharina ^a   Twiss, James ^b   Speich, Rudolf ^c   McKenna, Stephen P ^b   Grünig, Ekkehard ^d   Kähler, Christian M ^a   Ehlken, Nicola ^d   Treder, Ursula ^c   Crawford, Sigrid R ^b   Huber, Lars C ^c   Ulrich, Silvia ^c  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b GALEN RESEARCH   (United Kingdom)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Chronic thromboembolic pulmonary hypertension; German adaptation; Patient reported outcome; Pulmonary arterial hypertension; Pulmonary hypertension; Quality of life

Indexed keywords

OXYGEN;

ADULT; ARTICLE; CAMBRIDGE PULMONARY HYPERTENSION OUTCOME REVIEW; CLINICAL ASSESSMENT TOOL; COGNITIVE DEBRIEFING INTERVIEW; CONSTRUCT VALIDITY; DISEASE SEVERITY; FEMALE; GERMANY; HUMAN; INTERNAL CONSISTENCY; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PSYCHOMETRY; PULMONARY HYPERTENSION; RELIABILITY; REPRODUCIBILITY;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; DIAGNOSTIC SELF EVALUATION; FEMALE; GERMANY; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TRANSLATING; YOUNG ADULT;

EID: 84866137773     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-10-110     Document Type: Article

References (31)

1. Humbert M, Sitbon O, Yaïci A, Montani D, O'Callaghan DS, Jaïs X, Parent F, Savale L, Natali D, Günther S, Chaouat A, Chabot F, Cordier JF, Habib G, Gressin V, Jing ZC, Souza R, Simonneau G, . French Pulmonary Arterial Hypertension Network Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010, 36:549-55. 10.1183/09031936.00057010, 20562126, French Pulmonary Arterial Hypertension Network.
2. Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management (REVEAL). Chest 2011, 141(2):363-373.
3. Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, Hodgkins D, Goldsmith K, Hughes RJ, Sheares K, Tsui SS, Armstrong IJ, Torpy C, Crackett R, Carlin CM, Das C, Coghlan JG, Pepke-Zaba J. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008, 177:1122-1127. 10.1164/rccm.200712-1841OC, 18292468.
4. McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, Gibbs JS, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:S97-S107. 10.1016/j.jacc.2009.04.007, 19555863.
5. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010, 122:164-172. 10.1161/CIRCULATIONAHA.109.898122, 20585012.
6. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117:3010-3019. 10.1161/CIRCULATIONAHA.107.742510, 18506008.
7. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008, 52:2127-2134. 10.1016/j.jacc.2008.08.059, 19095129.
8. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB, . PACES Study Group Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149:521-530. PACES Study Group.
9. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903. 10.1161/CIRCULATIONAHA.108.839274, 19470885.
10. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329. 10.1056/NEJMoa020204, 12151469.
11. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW, . for the Primary Pulmonary Hypertension Study Group A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296-302. 10.1056/NEJM199602013340504, 8532025, for the Primary Pulmonary Hypertension Study Group.
12. Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 2009, 135:137-142. 10.1378/chest.07-0275, 18812447.
13. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010, 55:1915-1922. 10.1016/j.jacc.2010.01.027, 20430262.
14. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800-804.
15. Cenedese E, Speich R, Dorschner L, Ulrich S, Maggiorini M, Jenni R, Fischler M. Measurement of Quality of Life in pulmonary hypertension and its significance. Eur Respir J 2006, 28:808-815. 10.1183/09031936.06.00130405, 16707511.
16. Chen H, De Marco T, Kobashigawa EA, Katz PP, Chang VW, Blanc PD. Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension. Eur Respir J 2011, 38:608-616. 10.1183/09031936.00161410, 3158810, 21273391.
17. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006, 15:103-115. 10.1007/s11136-005-3513-4, 16411035.
18. ATS Statement:guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117. ATS.
19. Wilsher M, Good N, Hopkins R, Young P, Milne D, Gibson A, Suppiah R, Ly J, Doughty R, Dalbeth N. The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease. Respirology 2012, 17(4):647-652. May, 10.1111/j.1440-1843.2012.02133.x, 22256786.
20. Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler 2008, 14(3):383-390. Apr, 10.1177/1352458507082607, 17942508.
21. Sciurba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, Wise RA. National Emphysema Treatment Trial Research Group. Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med 2003, 167:1522-1527. 10.1164/rccm.200203-166OC, 12615634.
22. Gomberg-Maitland M, Huo D, Benza RL, McLaughlin VV, Tapson VF, Barst RJ. Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. J Heart Lung Transplant 2007, 26:732-738. 10.1016/j.healun.2007.04.013, 17613405.
23. Oudiz RJ, Barst RJ, Hansen JE, Sun XG, Garofano R, Wu X, Wasserman K, et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol 2006, 97:123-126. 10.1016/j.amjcard.2005.07.129, 16377296.
24. The Criteria Committee of the New York Heart Association Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels 1994, 253-256. Little, Brown & Co, Boston, Mass, 9, The Criteria Committee of the New York Heart Association.
25. Hunt SM, McEwen J. McKenna SP 1986, Croom Helm, Measuring Health Status London.
26. Gomberg-Maitland M, Thenappan T, Rizvi K, Chandra S, Meads DM, McKenna SP. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant 2008, 27:124-130. 10.1016/j.healun.2007.10.004, 18187098.
27. Coffin D, Duval K, Martel S, Granton J, Lefebvre MC, Meads DM, Twiss J, McKenna SP. Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J 2008, 15:77-83. 2677839, 18354747.
28. Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology 2011, 16:1235-1240. 10.1111/j.1440-1843.2011.02030.x, 21810146.
29. McKenna SP, Hunt SM, Tennant A. The development of a patient-completed index of distress from the Nottingham Health Profile: A new measure for use in cost-utility studies. Br J Med Econ 1993, 6:13-24.
30. McKenna SP, Ratcliffe J, Meads DM, Brazier JE. Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes 2008, 6:65. 10.1186/1477-7525-6-65, 2546377, 18718016.
31. Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J, Pepke-Zaba J. The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J 2008, 32:1513-1519. 10.1183/09031936.00069708, 18768576.